je.st
news
Tag: hepatitis
J&J Hepatitis C Drug Wins U.S. Approval as Therapy With Sovaldi
2014-11-06 15:21:29| Food - Topix.net
Johnson & Johnson won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc.'s Sovaldi, making it the second all-oral treatment available for the most common form of the virus. The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement.
Tags: with
drug
approval
therapy
Medivir and county councils conclude agreement on Olysio -based treatment for hepatitis C
2014-10-30 10:28:16| Appliances - Topix.net
Medivir AB announces that the company has entered into an agreement with Swedish county councils regarding the treatment of hepatitis C with OlysioA . The Dental and Pharmaceutical Benefits Agency has concluded that treatment with OlysioA is beneficial from a health economics viewpoint in the treatment of HCV genotypes 1 and 4 with METAVIR scores of F3-F4, irrespective of previous treatment.
Tags: c
based
agreement
county
Insurers May Cover Costly Hepatitis C Drugs Only For The Very Ill
2014-10-29 02:01:08| Biotech - Topix.net
Gilead's once-a-day pill for hepatitis C is the latest expensive and effective treatment that insurers say is a business challenge. In the past year, hepatitis C drugs that promise higher cure rates and fewer side effects have given fresh hope to millions who are living with the chronic liver disease.
Gilead's $1,000-a-pill hepatitis C drug may make financial sense for prisons
2014-10-21 15:36:50| Biotech - Topix.net
Sovaldi's $1,000-a-pill price has grabbed headlines, but a new study suggests it may actually be cost effective for prison systems. Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers.
Tags: make
financial
sense
drug
New Hepatitis C med approved
2014-10-11 07:16:24| Biotech - Topix.net
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved Harvoni , the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, approved under the tradename Sovaldi in December 2013.
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »